Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses
Research and development	$ 9,712	$ 7,591
General and administrative	6,804	6,189
Total operating expenses	16,516	13,780
Loss from operations	(16,516)	(13,780)
Other income (expense), net
Interest income and other, net	891	15
Interest expense and other, net	(1,207)	0
Loss before income taxes	(16,832)	(13,765)
Income tax expense		(63)
Net loss	(16,832)	(13,828)
Net loss attributable to non-controlling interest	(8,460)	(7,605)
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (8,372)	$ (6,223)
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., basic	$ (0.33)	$ (0.29)
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted	$ (0.33)	$ (0.29)
Weighted-average share outstanding basic	25,240	21,409
Weighted-average share outstanding diluted	25,240	21,409
Common Class A [Member]
Other income (expense), net
Net loss attributable to Rani Therapeutics Holdings, Inc.	$ (8,372)	$ (6,223)
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., basic	$ 0.33	$ 0.29
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted	$ 0.33	$ 0.29
Weighted-average share outstanding basic	25,240	21,409
Weighted-average share outstanding diluted	25,240	21,409